Journal article
Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma
Journal of pediatric hematology/oncology, v 46(2), pp e184-e187
Mar 2024
PMID: 38099690
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Anaplastic lymphoma kinase (ALK)-fusion sarcomas are rare part of the emerging theoretically targetable tyrosine kinase RAS::MAPK pathway fusion myopericytic-ovoid sarcomas. We report our clinicopathologic and treatment experience with an ALK fusion sarcoma. A novel ELKS/RAB6-interacting/CAST family member 1–unaligned ALK fusion infiltrative nonmetastatic low-grade sarcoma of the right hand of a 15-month-old male was treated with crizotinib, an ALK tyrosine kinase inhibitor as oral monotherapy, inducing complete radiographic and clinical resolution by 10 months and sustained response now over 12 months after elective discontinuation. Crizotinib can successfully be used to treat unresectable novel ALK fusion sarcomas.
Metrics
1 Record Views
Details
- Title
- Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma
- Creators
- Megan L. Wood - Stony Brook UniversityJulie C. Fanburg-Smith - St. Christopher's Hospital for ChildrenJames M. Brian - St. Christopher's Hospital for ChildrenJason C. White - St. Christopher's Hospital for ChildrenJonathan L. Powell - Nemours Children's Health SystemAndrew S. Freiberg - Penn State Milton S. Hershey Medical Center
- Publication Details
- Journal of pediatric hematology/oncology, v 46(2), pp e184-e187
- Publisher
- Lippincott Williams & Wilkins
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:001177433500001
- Scopus ID
- 2-s2.0-85186268903
- Other Identifier
- 991022202113804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Hematology
- Oncology
- Pediatrics